- •BRCA 1/2 carriers report higher rates of cascade genetic testing in their families compared to those with Lynch Syndrome.
- •Less than half of at-risk first-degree family members go on to obtain testing for germline BRCA or Lynch mutations.
- •Cascade genetic testing rates are significantly higher in female family members compared to male family members.
- •Letters to at-risk family members by gynecologic oncology practices may facilitate cascade genetic testing.
- Inherited mutations in women with ovarian carcinoma.JAMA oncology. 2016; 2: 482-490
- Identification of Lynch syndrome among patients with colorectal cancer.Jama. 2012; 308: 1555-1565
- Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.Cancer. 2015; 121: 25-33
- Prevalence and penetrance of major genes and polygenes for colorectal cancer.Cancer Epidemiol Biomarkers Prev. 2017; 26: 404-412
- Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions.Am. J. Public Health. 2009; 99: 2203-2209
- Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.J. Clin. Oncol. 2008; 26: 1331-1337
- Genetic/familial high risk assessment: breast and ovarian.https://http://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdfDate: 2019
- Evolving paradigms in research and care in ovarian cancers.Obstet. Gynecol. 2016; 128: 771-774
- National estimates of genetic testing in women with a history of breast or ovarian cancer.J. Clin. Oncol. : official journal of the American Society of Clinical Oncology. 2017; 35: 3800-3806
- Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations.Genet. Test. 2008; 12: 81-91
- Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.Clin. Genet. 2015; 88: 182-186
- Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder.J. Med. Genet. 2006; 43: 665-670
- Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program’s experience.Am. J. Med. Genet. Part C, Seminars in medical genetics. 2003; 119C: 11-18
- What women with ovarian cancer think and know about genetic testing.Gynecol. Oncol. 2008; 111: 132-136
- Accuracy of recall of information about a cancer-predisposing BRCA1/2 gene mutation among patients and relatives.Eur. J. Hum. Genet. 2015; 23: 147-151
- The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety.Fam. Cancer. 2016; 15: 155-162
- Limitations and pitfalls of using family letters to communicate genetic risk: a qualitative study with patients and healthcare professionals.J. Genet. Couns. 2018; 27: 689-701
- Cascade testing in familial hypercholesterolaemia: how should family members be contacted?.Eur. J. Hum. Genet. 2005; 13: 401-408
- Cardiovascular cascade genetic testing: exploring the role of direct contact and technology.Front Cardiovasc Med. 2016; 3: 11
- Family letters are an effective way to inform relatives about inherited cardiac disease.Am. J. Med. Genet. 2009; 149A: 357-363
- ACOG committee opinion No. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer.Obstet. Gynecol. 2018; 131: e31-e34
- Ovarian cancer risk factors in African-American and white women.Am. J. Epidemiol. 2009; 170: 598-606
- Cascade screening: whose information is it anyway?.Eur. J. Hum. Genet. 2005; 13: 397-398
☆Presented as a poster at the 2019 Society of Gynecologic Oncology Annual Meeting.